Showing 1931-1940 of 2150 results for "".
- Alexander van der Mey Named New CCO at Optimo Medical AGhttps://modernod.com/news/alexander-van-der-mey-named-new-cco-at-optimo-medical-ag/2477248/As of January 16, Alexander van der Mey assumed the role of chief commercial officer (CCO) position of Optimo Medical AG. In his new position, Mr. van der Mey is responsible for global marketing and sales. Mr. Van der Mey has studied business administration in Germany and the Netherlands.
- Aerie Pharmaceuticals Announces FDA Approval of its Athlone, Ireland Facility for Production of Rocklatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-fda-approval-of-its-athlone-ireland-facility-for-production-of-rocklatan/2477245/Aerie Pharmaceuticals announced that its sterile fill production facility in Athlone, Ireland has received approval from FDA to produce Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful preapprov
- Hoya Surgical Optics Launches Joint Venture With GeMax in Chinahttps://modernod.com/news/hoya-surgical-optics-launches-joint-venture-with-gemax-in-china/2477238/Hoya Surgical Optics (HSO) announced a new joint venture with GeMax, a specialty promotion service provider of IOLs with a strong market position and reputation in China, covering more than 630 major hospitals in 32 provinces. The joint venture will be named Hoya GeMax Medical. HSO will be the ma
- CRST: 2019 Year in Focushttps://modernod.com/news/2019-year-in-focus/2477197/Fueled by an influx of investment capital in recent years and a streamlined regulatory review process, the number of ophthalmic products approved or introduced in 2019 continued to rise steadily throughout the year. According to recent figures from pharmaceutical market research company Strategic
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- AI Diagnostics Company IDx Announces New Appointments to its Executive Leadership Teamhttps://modernod.com/news/ai-diagnostics-company-idx-announces-new-appointments-to-its-executive-leadership-team/2477153/IDx Technologies announced several new appointments to its executive leadership team to accelerate product development and scale operations to accommodate increased market adoption of IDx-DR, according to a company news release. IDx-DR is an FDA-authorized autonomous AI system that detects diabet
- RightEye Vision System Receives Breakthrough Device Designation from the FDA for Parkinson’s Disease Testhttps://modernod.com/news/righteye-vision-system-receives-breakthrough-device-designation-from-the-fda-for-parkinsons-disease-test/2477133/RightEye announced that the RightEye Vision System has received breakthrough device designation from the FDA for a Parkinson’s Disease Test. The designation is designed to streamline the market clearance
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Drug Rhokiinsahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-drug-rhokiinsa/2477111/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension. The marketing authorization a
- Report: Novartis Weighing Takeover Offer for The Medicines Companyhttps://modernod.com/news/report-novartis-weighing-takeover-offer-for-the-medicines-company/2477107/Novartis is considering making an offer to acquire The Medicines Company and is currently conducting due diligence on the drugmaker, Bloomberg reported Tuesday, citing people close to the matter. The sources suggested that The Medicines Company, which has a market value of about $4.7 bi
- ELT Sight Acquires Assets and IP of MLase AG Excimer Ophthalmic Laser System for Glaucoma Surgeryhttps://modernod.com/news/elt-sight-acquires-assets-and-ip-of-mlase-ag-excimer-ophthalmic-laser-system-for-glaucoma-surgery/2477086/ELT Sight announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. Terms for the acquisition were not disclosed. MLase manufactures and markets laser systems, including the ExTra ELT Laser and disposable applicator used